Free Trial
→ The Executive Order That Quietly Changed What Your Dollar Means (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q3 2026 Earnings Date & Estimates

Innoviva logo
$21.21 +0.34 (+1.63%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$21.09 -0.12 (-0.57%)
As of 10/9/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innoviva is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Innoviva in Q3 2026

Innoviva is expected to post earnings of $0.49 per share on revenue of $115.31 million. In the same quarter a year earlier Innoviva reported $1.08 per share on revenue of $107.80 million. Innoviva last reported on May 6, 2026, posting $0.44 per share and beating the $0.43 consensus estimate. Innoviva has beaten the consensus EPS estimate in 4 of its last 5 quarters.

Consensus Estimates

Consensus EPS
$0.49
Expected Revenue
$115.31 million
Prior-Year EPS
$1.08
Prior-Year Revenue
$107.80 million
Expected EPS Growth
-54.6%
Expected Revenue Growth
+7.0%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
$0.44 (Beat by +$0.01)
Last Quarter Revenue
$97.99 million
EPS Beat Rate
4 of last 5 quarters

Prepare for the Q3 2026 Call

Innoviva Q3 2026 Earnings FAQ

Innoviva (NASDAQ:INVA) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Innoviva's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Innoviva to post earnings of $0.49 per share for Q3 2026.

The consensus revenue estimate for Innoviva is $115.31 million for Q3 2026.

Innoviva Earnings Headlines

Analyzing Innoviva (NASDAQ:INVA) & Assembly Biosciences (NASDAQ:ASMB)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107656
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
October 8 at 7:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/innoviva-inva-undervalued-zacks-flags-191909404.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 11 at 1:00 AM  |  Base Camp Trading (Ad)
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
September 28, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/62030831/zymeworks-updates-annual-financial-targets-after-finalizing-theravance-biopharma-deal
Theravance Biopharma Completes Merger and Plans Nasdaq Delisting
September 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/theravance-biopharma-completes-merger-and-plans-nasdaq-delisting?utm_source=marketbeat.com&utm_medium=referral
Zymeworks Closes Theravance Acquisition and CVR Financing
September 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zymeworks-closes-theravance-acquisition-and-cvr-financing?utm_source=marketbeat.com&utm_medium=referral
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA) is a healthcare company focused on acquiring, developing and commercializing pharmaceutical assets, with a particular emphasis on medicines for respiratory and infectious diseases. The company generates a substantial portion of its business through royalty interests in marketed products and also invests in healthcare companies and development-stage therapies.

Innoviva holds royalty rights related to several respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which is marketed as Relvar Ellipta in some international markets. These inhaled therapies are used to treat conditions such as chronic obstructive pulmonary disease and asthma. Innoviva has also held interests in other respiratory and anti-infective products through licensing arrangements and corporate investments.

The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2016 following the separation of its operations from Theravance Biopharma. Based in Burlingame, California, Innoviva serves international healthcare markets through its licensing partnerships, royalty agreements and portfolio companies. Its activities include supporting the development and commercialization of medicines while seeking additional opportunities in biopharmaceuticals.

View Innoviva Profile
Earnings Tools